A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease

Phase 2

Completed

• Conditions: Type 2 Diabetes Mellitus; Chronic Kidney Disease
• Interventions: Biological: Renal Autologous Cell Therapy (REACT)

• Registration Number: NCT03270956
• Lead Sponsor: Prokidney

Brief Summary

The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).

Detailed Description

All subjects enrolled will receive REACT. Subjects will receive their first REACT injection as soon as the REACT product is manufactured and shipped to the clinical site. After 6 months (+4 weeks), a second injection will be given, as appropriate. Each subject's baseline rate of renal decline, based on adequate historical clinical data obtained 24 months prior to screening visit, will serve as a comparator for monitoring the rate of progression of renal insufficiency over time.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2017-08-25
• Study First Submitted QC: 2017-08-31
• Study First Posted: 2017-09-01
• Study Start: 2018-04-25
• Primary Completion: 2022-11-17
• Study Completion: 2022-11-17
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-06
• Last Update Posted: 2023-01-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. The subject is male or female, 30 to 65 years of age on the date of informed consent.
2. The subject has an established diagnosis of T2DM.
3. The subject has an established diagnosis of diabetic nephropathy as the underlying cause of renal disease.
4. The subject has an established diagnosis of CKD not requiring renal dialysis, defined as having an eGFR between 14 and 20 mL/min/1.73m² inclusive at the Screening Visit and prior to REACT injection.
5. The subject has blood pressure less than 150/90 at the Screening Visit, prior to renal biopsy, and prior to REACT injection(s). Note BP should not be significantly below the previously recorded stable pressure.
6. A minimum of 3 measurements of eGFR or sCr should be obtained at least 3 months apart prior to the Screening Visit or within the previous 24 months to define the rate of progression of CKD. The subject should have adequate, historical clinical data to provide a reasonable estimate of the rate of progression of CKD. The Medical Monitor may be consulted to ensure there is sufficient data.

Read More

Exclusion Criteria

1. The subject has a history of type 1 diabetes mellitus.
2. The subject has a history of renal transplantation.
3. The subject has a serum HbA1c level greater than 10% at the Screening Visit.
4. The subject has uncontrolled diabetes (defined as metabolically unstable by the Investigator).
5. The subject has hemoglobin levels less than 9 g/dL prior to each REACT injection.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Renal Autologous Cell Therapy (REACT)	Renal Autologous Cell Therapy (REACT)	Renal Autologous Cell Therapy (REACT) Treatment - Patients will receive their first treatment of 2 injections of REACT as soon as REACT product is made available.

Primary Outcome Measures

Name	Time	Method
Procedure and/or product related adverse events	Through 24 months following last REACT injection	Incidence (percentage of subjects) with procedure and/or product related adverse events by System Order Class and Preferred Term

Secondary Outcome Measures

Name	Time	Method
Renal specific adverse events	Through 24 months following last REACT injection	Incidence (percentage of subjects) with renal-specific adverse events by System Order Class and Preferred Term

Trial Locations

Locations (4)

University of Arizona [WITHDRAWN]; 🇺🇸 Tucson, Arizona, United States

Boise Kidney & Hypertension Institute; 🇺🇸 Boise, Idaho, United States

University of North Carolina- Chapel Hill; 🇺🇸 Chapel Hill, North Carolina, United States

Vanderbilt University [WITHDRAWN]; 🇺🇸 Nashville, Tennessee, United States